XBIO (Xenetic Biosciences) E10: $-147.87 (As of Mar. 2026)


XBIO Xenetic Biosciences Inc XBIO
83 GF Score
Price $2.98
GF Value $4.18
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences E10?

Xenetic Biosciences XBIO -3.23% 83 E10 is $-147.87 as of Mar. 2026. GuruFocus rates XBIO with a GF Score™ of 83/100 and a GF Value™ of $4.18 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Xenetic Biosciences's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.200. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-147.87 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 16.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Xenetic Biosciences was 16.50% per year. The lowest was 9.40% per year. And the median was 12.95% per year.

As of today (2026-06-30), Xenetic Biosciences's current stock price is $2.98. Xenetic Biosciences's E10 for the quarter that ended in Mar. 2026 was $-147.87. Xenetic Biosciences's Shiller PE Ratio of today is .


Xenetic Biosciences  (NAS:XBIO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Xenetic Biosciences E10 Related Terms


Xenetic Biosciences E10 Historical Data

* Premium members only.

The historical data trend for Xenetic Biosciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences E10 Chart

Xenetic Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -271.93 -271.53 -252.84 -202.25 -157.83

Xenetic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -194.27 -191.61 -172.34 -157.83 -147.87

XBIO vs ACXP, SILO, GOVX: E10 Comparison

For the Biotechnology subindustry, Xenetic Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's Shiller PE Ratio falls into.


XBIO
83GF Score
Xenetic Biosciences Inc XBIO
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenetic Biosciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xenetic Biosciences's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.2/330.2130*330.2130
=-0.200

Current CPI (Mar. 2026) = 330.2130.

Xenetic Biosciences Quarterly Data

per share eps CPI Adj_EPS
201606 -734.403 241.018 -1,006.188
201609 -33.600 241.428 -45.956
201612 -36.000 241.432 -49.238
201703 -40.800 243.801 -55.261
201706 -40.800 244.955 -55.001
201709 -31.200 246.819 -41.742
201712 62.400 246.524 83.583
201803 -25.200 249.554 -33.345
201806 -27.800 251.989 -36.430
201809 -23.100 252.439 -30.217
201812 -20.800 251.233 -27.339
201903 -64.500 254.202 -83.787
201906 -15.600 256.143 -20.111
201909 -26.700 256.759 -34.338
201912 -1.929 256.974 -2.479
202003 -1.900 258.115 -2.431
202006 -1.500 257.797 -1.921
202009 -12.000 260.280 -15.224
202012 -1.500 260.474 -1.902
202103 -1.500 264.877 -1.870
202106 -1.300 271.696 -1.580
202109 -1.300 274.310 -1.565
202112 -1.400 278.802 -1.658
202203 -1.200 287.504 -1.378
202206 -1.900 296.311 -2.117
202209 -0.560 296.808 -0.623
202212 -0.970 296.797 -1.079
202303 -0.560 301.836 -0.613
202306 -0.690 305.109 -0.747
202309 -0.690 307.789 -0.740
202312 -0.770 306.746 -0.829
202403 -0.780 312.332 -0.825
202406 -0.830 314.175 -0.872
202409 -0.280 315.301 -0.293
202412 -0.680 315.605 -0.711
202503 -0.590 319.799 -0.609
202506 -0.450 322.561 -0.461
202509 -0.330 324.800 -0.335
202512 -0.220 324.054 -0.224
202603 -0.200 330.213 -0.200

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-147.87 mean?
Xenetic Biosciences (XBIO) has a E10 of $-147.87 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Xenetic Biosciences and its competitors.
Is Xenetic Biosciences' E10 too high?
Xenetic Biosciences' current E10 is $-147.87. Overall, Xenetic Biosciences has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' E10 compare to ACXP and SILO?
Xenetic Biosciences' E10 of $-147.87 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current E10 is $-147.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.18, compared to a current price of $2.98 — trading 28.7% below its estimated fair value. The current E10 is $-147.87. Xenetic Biosciences' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current E10 is $-147.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of $2.98 is trading 28.7% below its estimated GF Value™ of $4.18. GuruFocus considers Xenetic Biosciences to be Modestly Undervalued.

Key valuation signals for XBIO:

  • E10: $-147.87
  • GF Value™: $4.18 vs. price of $2.98 (28.7% below fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xenetic Biosciences Business Description

Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
83GF Score

Get the complete analysis for XBIO

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.98
Price
$4.18
GF Value